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ABSTRACT
Background and aims Leucocyte migration to gut
mucosa, mediated by integrin binding to mucosal
addressin cell adhesion molecule (MAdCAM), is
a promising target for therapeutic intervention in
inflammatory bowel disease. This first-in-human study of
a monoclonal antibody to MAdCAM, PF-00547,659,
aimed to explore the safety and preliminary efficacy of
this gut-specific mechanism in ulcerative colitis.
Methods In this randomised, double-blind placebo-
controlled study, 80 patients with active ulcerative colitis
received single or multiple (three doses, 4-week
intervals) doses of PF-00547,659 0.03e10 mg/kg IV/SC,
or placebo. Safety was assessed by adverse events,
laboratory tests, and immunogenicity. Exploratory
efficacy analyses were based on Mayo score and
endoscopic responder rates at weeks 4 and 12. Faecal
calprotectin was quantified as a measure of disease
activity, and the number of a4b7
+ lymphocytes was
measured to demonstrate drug activity.
Results No obvious drug-related side effects were
observed in the PF-00547,659 group, while patient
numbers, especially those fully exposed, were small.
Overall responder/remission rates at 4 and 12 weeks
were 52%/13% and 42%/22%, respectively with
combined PF-00547,659 doses compared with 32%/11%
and 21%/0%, respectively with placebo. Equivalent
endoscopic responder rates were 50% and 42% versus
26% and 29%, respectively. Faecal calprotectin levels
decreased to a greater extent with PF-00547,659 than
placebo (week 4: 63% vs 18%). Despite variability, there
was a trend for an increase in a4b7
+ lymphocytes in
patients receiving PF-00547,659.
Conclusions The favourable short-term safety profile
and preliminary efficacy findings for PF-00547,659 in this
first-in-human study pave the way for further
investigation in larger trials, to establish the role of
PF-00547,659 in ulcerative colitis treatment.
Trial Register No: NCT00928681.
INTRODUCTION
Biological therapies have an established role in the
management of moderate-to-severe inﬂammatory
bowel disease (IBD) that is refractory to conven-
tional treatments. Currently, the only biological
treatments for IBD which are licensed worldwide
target tumour necrosis factor a (TNFa) (inﬂiximab,
adalimumab and certolizumab pegol for Crohn’s
disease, and inﬂiximab for ulcerative colitis). While
anti-TNF agents provide a signiﬁcant advance in
the treatment of refractory IBD, with short-term
clinical response rates of approximately 60e70% in
ulcerative colitis and Crohn’s disease, primary and
secondary treatment failure remain a problem for
many patients.1e4 Furthermore, there are safety
concerns with anti-TNF agents, including suscep-
tibility to intracellular opportunistic infections
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Significance of this study
What is already known about this subject?
< Despite the fact that biological therapies
targeting tumour necrosis factor a (TNFa)
have significantly advanced the management
of patients with inflammatory bowel disease
(IBD), there is a remaining need for efficacious
drugs with good safety profiles.
< Homing of leucocytes to the gut mucosa is
a promising target for therapeutic intervention in
IBD, shown by studies with the a4-integrin
antibody natalizumab in Crohn’s disease and
ulcerative colitis.
< However, natalizumab is not available to treat
Crohn’s disease in Europe given the risk of
progressive multifocal leucoencephalopathy
(PML).
< To avoid this, more selective strategies
targeting the a4b7/MAdCAM pathway in the
gut would be expected to confer similar efficacy
as seen with natalizumab but a better safety
profile.
What are the new findings?
< This is the first study of PF-00547,659, a highly
specific, fully human anti-MAdCAM IgG2 anti-
body in patients with active ulcerative colitis.
< Study results show that single and multiple
doses of PF-00547,659 were safe and well
tolerated with no evidence of immunogenicity.
< Furthermore, preliminary efficacy findings were
promising with higher response and remission
rates for PF-00547,659 as compared to placebo.
How might it impact on clinical practice in the
foreseeable future?
< PF-00547,659 is a promising target for larger
phase II studies in ulcerative colitis.
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such as tuberculosis, and the potential risk of lymphoma and
other malignancies.5 6 Therefore, a need remains for efﬁcacious
drugs with good safety proﬁles, to improve patient outcomes in
the debilitating conditions of Crohn’s disease and ulcerative
colitis.
Homing of leucocytes to the gut mucosa is a promising target
for therapeutic intervention in IBD, shown by studies with the
a4-integrin antibody natalizumab in Crohn’s disease7e9 and
ulcerative colitis.10 However, the use of natalizumab is limited
by well-publicised concerns over the risk of progressive multi-
focal leucoencephalopathy (PML),11e13 an opportunistic infec-
tion of the central nervous system (CNS) by the polyomavirus
JC virus.14 Susceptibility to PML may arise as a result of
disruption of immune surveillance in the CNS, which may be
mediated in part by homing of a4b1-positive leucocytes to
vascular cell adhesion molecule (VCAM).15e18 The effects of
natalizumab in the gut likely involvedamong other mecha-
nisms (including inhibition of a4b1 integrin)danother popula-
tion of cells expressing a4-integrinea4b7-positive (a4b7+)
leucocytes, which bind mucosal addressin cell adhesion molecule
(MAdCAM).19e21
MAdCAM is expressed predominantly on vascular endothe-
lium in the intestinal lamina propria.22 Animal studies conﬁrm
the importance of MAdCAM in gut inﬂammation in colitis,23e25
and suggest that VCAM has a comparatively minor role.26e28
Selectively targeting the a4b7/MAdCAM pathway, to attenuate
leucocyte trafﬁcking in the gut without disrupting VCAM-
mediated leucocyte homing in other organs, would be expected
to confer similar efﬁcacy in IBD to that seen with a less selective
anti-leucocyte trafﬁcking mechanism, but with potential safety
beneﬁts due to the more localised effect. The concept of
selectively targeting the a4b7/MAdCAM pathway for IBD
treatment is supported by animal studies,23 29 and initial clinical
results with vedolizumab (MLN0002), a humanised monoclonal
antibody for a4b7-integrin.30 31
While natalizumab and vedolizumab target integrins,
blockade of MAdCAM itself is a gut-speciﬁc therapeutic mech-
anism for IBD. Importantly, for reducing the risk of CNS
infections such as PML, immunohistochemistry studies conﬁrm
an absence of MAdCAM expression in the human brain.32
PF-00547,659 is a highly speciﬁc, fully human anti-MAdCAM
IgG2 antibody.33 We report the ﬁrst study of PF-00547,659 in
humans, in patients with active ulcerative colitis
(NCT00928681, http://ClinicalTrials.gov/). The primary objec-
tive was to investigate the safety and tolerability of single and
multiple doses of PF-00547,659. We also performed exploratory
efﬁcacy assessments based on clinical and endoscopic indices of
ulcerative colitis activity, and explored effects on number of
circulating CD4+ a4b7+ lymphocytes (a mechanistic biomarker),
faecal calprotectin (a biomarker for disease activity), and plasma
high-sensitivity C reactive protein (hsCRP; a biomarker for
inﬂammation).
METHODS
Study design, patients and setting
This was a randomised, double-blind (sponsor-open), placebo-
controlled, dose-escalating, parallel-group study. Patients were
assigned to one of six single-dose or ﬁve multiple-dose cohorts,
and within each cohort were randomised to receive placebo or
PF-00547,659. Randomisation was conducted using a sequential
numbering system based on the order of patient enrolment.
In the single-dose study phase, patients received single intra-
venous (IV) infusion of PF-00547,659 at doses of 0.03, 0.1, 0.3,
1.0 or 10 mg/kg or a single subcutaneous (SC) injection of PF-
00547,659 at dose of 3.0 mg/kg, or matching placebo. Patients in
the multiple-dose phase received three doses, 4 weeks apart, of
PF-00547,659 at doses of 0.1, 0.3 or 3.0 mg/kg IV or 0.3 or
1.0 mg/kg SC, or placebo (ﬁgure 1). PF-00547659 was presented
as a sterile, isotonic solution containing 10 mg/ml PF-00547659
in an acetate buffer solution containing mannitol, Polysorbate
and ethylenediaminetetraacetic acid (pH 5.5). Sodium chloride
solution 0.9% w/v BP was used as the placebo.
Follow-up continued for 12 weeks in the single-dose phase and
16 weeks in the multiple-dose phase. If PF-00547,659 remained
detectable in blood plasma at the last clinic visit, follow-up
continued at 4-week intervals until drug concentrations fell
below the detection limit of 20 ng/ml. To maintain blinding,
some patients on placebo were followed up over an extended
period.
Inclusion criteria
Male and female patients aged 18e70 years, with a histologi-
cally conﬁrmed diagnosis of ulcerative colitis for at least
3 months prior to study entry, were enrolled. Patients were
required to have active ulcerative colitis (total Mayo score $6,
endoscopic subscore $2), despite being on stable doses of
5-aminosalicylic acid (5-ASA) or sulfasalazine for 3 weeks; or
azathioprine or 6-mercaptopurine for 3 months, which were to
be continued throughout the study; or oral steroids (up to
40 mg/day prednisolone or equivalent) for 2 weeks, which could
be tapered at the investigator ’s discretion.
Exclusion criteria
Patients were excluded from the study if they had ulcerative
colitis conﬁned to proctitis; fulminant colitis; history of malig-
nant neoplasia; renal or hepatic impairment; signiﬁcant cardio-
vascular disease in the previous 12 months; hepatitis B, hepatitis
C or HIV infection; evidence of pathogenic infection in faecal
culture; history of steroid dependence (determined at the
investigator ’s discretion); or allergic disease or sensitivity to
heparin.
Patients were also excluded if they had undergone surgery for
ulcerative colitis or were likely to require surgery during the
study, or if they had used methotrexate, mycophenolate,
cyclosporine or biological therapy within 3 months prior to
study dosing, interferon or leucocyte apheresis within
12 months, intravenous steroids within 1 month, any rectally
administered treatment within 1 week, or had previously used
natalizumab or PF-00547,659. Women were excluded if they
were pregnant or lactating.
Ethics
The research protocol was approved by the appropriate insti-
tutional review board or independent ethics committee for each
study site. All participants gave written informed consent.
Study procedures
Safety evaluations
All adverse events (AEs) and the likely relationship to study
treatment were recorded. Additional safety evaluations included
laboratory tests, vital signs, and 12-lead ECG. To assess whether
PF-00547,659 induced an immunogenic response, antidrug
antibodies were measured in serum from blood samples taken
predose and every 4 weeks up to week 12.
In the evaluation of efﬁcacy and biomarker data, week 4 of the
single-dose cohorts and predose week 4 of the multiple-dose
cohorts were combined in the week 4 timepoint assessment.
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Efficacy evaluations: Mayo scores
Mayo scores34 were derived at week 4 and week 12 from disease
diaries completed by patients throughout the study (stool
frequency and rectal bleeding components), endoscopic exami-
nation by ﬂexible sigmoidoscopy, and the physician’s global
assessment. Mayo scores were summarised as responder rates
(proportion of patients with $3-point reduction and 30%
improvement in total Mayo score, and $1-point decrease in
rectal bleeding subscore or absolute rectal bleeding score of 0 or
1) and remission rates (proportion of patients with total Mayo
score #2 points with no individual subscore exceeding 1 point).
Endoscopic response was deﬁned as $1-point improvement in
endoscopic subscore, and endoscopic remission as endoscopic
subscore of 0 or 1. The proportion of patients with complete
mucosal healing (endoscopic subscore of 0) was also quantiﬁed.
Measurement of biomarkers
Feces and blood samples were collected predose and at intervals
during 12e16 weeks’ follow up, for measurement of faecal
calprotectin, hsCRP, and a4b7-expressing lymphocytes. Fecal
calprotectin was quantiﬁed by ELISA (ELISA, Calpro AS, Oslo,
Norway), while plasma hsCRP was quantiﬁed using a standard
in vitro diagnostic assay (Tina-Quant, Roche, Mannheim,
Germany). Lymphocyte sub-populations expressing a4b7-
integrin were determined in whole blood by 4-color ﬂow
cytometry using anti-a4 and anti-b7 antibodies (FACSCalibur
and antibodies, Becton Dickinson, New Jersey, USA) and analysed
with FloJo software (Tree Star Inc., Ashland, Oregon, USA).
Statistical methods
Sample sizes for this ﬁrst-in-human study were selected to
balance the need to minimise exposure of patients to
PF-00547,659 with the need to provide adequate safety and
tolerability information (primary outcome measure). The study
was not powered to detect statistically signiﬁcant differences in
clinical/endoscopic response or remission rates, and biomarkers
(secondary outcome measures).
Clinical response and remission rates were calculated for each
PF-00547,659 dose strength (IV and SC routes combined) at
weeks 4 and 12 to explore the doseeresponse relationship.
Clinical response and remission rates were also calculated for the
combined group of all PF-00547,659-treated patients, as were
endoscopic response and remission rates. Only patients in the
multiple-dose cohort were included in the week 12 analyses.
Clinical and endoscopic response and remission rates were
compared between PF-00547,659 (all dosages combined) and
placebo groups, at weeks 4 and 12, using Fisher ’s exact test
with a one-sided 5% signiﬁcance level (SAS; Release 8.02, SAS
Institute Inc., Cary, NC, USA). All patients who were rando-
mised and received at least one dose of study treatment were
included in efﬁcacy analyses; patients who discontinued due to
AEs or lack of efﬁcacy were considered treatment failures and
classed as non-responders.
Changes from baseline in natural log-transformed faecal
calprotectin and plasma hsCRP levels were compared between
PF-00547,659 and placebo at weeks 4 and 12, using an analysis of
variance (ANOVA) model that allowed for variation in baseline
levels. These results were back-transformed to give point esti-
mates of the percentage changes and associated 95% CI. Change
from baseline in CD4+ a4b7+ and CD4+ a4b7 lymphocytes was
summarised using descriptive statistics (mean, SD) for patients
receiving each PF-00547,659 dose strength and placebo, at weeks
4 and 12. For the CD4+ a4b7+ and CD4+ a4b7 lymphocyte
analyses, PF-00547,659-treated patients were also subdivided
into high-dose (1e10 mg/kg) and low-dose (0.03e0.3 mg/kg)
groups.
Figure 1 Study flow diagram. Patients
who discontinued the study due to lack
of efficacy or adverse events were
considered treatment failures and were
included as non-responders in efficacy
analyses. AE, adverse event; IV,
intravenous; SC, subcutaneous; UC,
ulcerative colitis.
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RESULTS
Patient demographics and disposition
Patients were enrolled at 17 sites in Europe from September
2005 to September 2008. In total, 80 patients were assigned
to treatment following screening: 30 to single-dose cohorts;
50 to multiple-dose cohorts (ﬁgure 1). Twenty-one patients
(70%) completed the single-dose study phase and nine (30%)
discontinued: ﬁve due to lack of efﬁcacy and four due to AEs
not considered to be related to study drug. Thirty patients (60%)
completed the multiple-dose phase of the study and 20
(40%) discontinued: 17 due to lack of efﬁcacy and three due to
AEs; one patient’s AEs were considered to be related to the study
drug (general physical health deterioration, frequent
bowel movements and abnormal laboratory tests, on
PF-00547,659 1 mg/kg SC). The majority of patients were white
males (possibly due to entry criteria excluding women
of childbearing potential at the start of the study; this was later
amended due to low recruitment to allow also females
of childbearing potential with adequate contraception),
with similar distributions of demographic and baseline clinical
characteristics across placebo and active treatment groups
(table 1).
Safety and tolerability
AEs were reported by similar proportions of patients on
PF-00547,659 and placebo. The most common AEs affected the
gastrointestinal system, including abdominal pain or tenderness;
few cases were considered treatment related (table 2). Most AEs
were mild or moderate in intensity.
Therewasno evidenceof opportunistic infections arising during
PF-00547,659 treatment, within or outside the gastrointestinal
system. Overall incidence of gastrointestinal tract infections was
low; ﬁve patients receiving PF-00547,659 and one receiving
placebo reported enteritis/gastroenteritis, but none of the cases
were considered by investigators to be related to study treatment.
Respiratory tract infections were infrequent. One case (moderate
upper respiratory tract infection) was considered potentially
related to PF-00547,659 treatment, although the patient was
also taking azathioprine, which could have increased suscepti-
bility. Few AEs affecting the central nervous system (CNS)
(mostly dizziness) were reported, with the majority of cases not
considered to be treatment related.
There were no deaths during the study. Three patients
reported nine serious AEs (SAEs) within the 16-week study (one
patient in each of the placebo, 3 mg/kg IV and 1 mg/kg SC
multiple-dose groups). Only the patient receiving PF-00547,659
1 mg/kg SC had SAEs that were investigator-assessed as poten-
tially related to treatment: rectal haemorrhage, general physical
health deterioration, joint (ankle) abscess, wound infection
(abdominal wall wound from proctocolectomy undertaken upon
worsening of ulcerative colitis), and abnormal laboratory tests
(elevated leucocyte count; low haemoglobin); this patient
discontinued the study. SAEs were recorded for six more patients
at follow-up visits after study end; these AEs were considered to
be related to underlying ulcerative colitis or other illnesses.
Laboratory test abnormalities did not suggest any treatment- or
dose-related patterns in changes in any parameter.
There was no evidence of an immunogenic response to the
drug as no anti-drug antibodies were detected in the presence of
the drug, or 1 month after the last injection, and no injection
site reactions were observed. Measurements at later time points
after complete disappearance of the drug would be needed to
Table 1 Demographic and baseline characteristics
Characteristic
Placebo (single and multiple
dose cohorts) (N[20)
PF-00547,659 (all active
treatment groups) (N[60)
Gender
Male 17 (85%) 52 (87%)
Race
White 20 (100%) 58 (97%)
Asian 0 1 (2%)
Hispanic 0 1 (2%)
Age (years), mean (SD) 47.9 (14.8) 45.1 (13.1)
Weight (kg), mean (SD) 83.7 (13.1) 80.2 (14.7)
Disease duration (years), median
(range)
6.5 (0.3e23.5) 6.2 (0.6e41.4)
Prior drug treatment for ulcerative colitis
Mesalazine 17 (85%) 47 (78%)
Azathioprine 6 (30%) 22 (37%)
Infliximab 4 (20%) 4 (7%)
Concomitant drug treatment for ulcerative colitis during the study
Mesalazine/prodrugs* 18 (90%) 50 (83%)
Azathioprine 4 (20%) 19 (32%)
Mercaptopurine 1 (5%) 1 (2%)
Steroidsy 8 (40%) 30 (50%)
Baseline total Mayo score, median (IQR) 7.5 (7.0e8.5) 8.5 (7.0e9.5)
Baseline faecal calprotectin (mg/kg),
geometric mean (95% CI)
N¼20 N¼57
733 (340 to 1578) 629 (425 to 932)
Baseline hsCRP (mg/dl), mean (SD) N¼19 N¼58
10.3 (11.2) 10.8 (21.4)
When the study commenced all women of childbearing potential were excluded; this criterion was subsequently relaxed to increase
enrolment of younger women and make the study population more representative of patients with ulcerative colitis seen in the clinic,
providing women of childbearing potential used at least two contraceptive methods.
*Predominantly mesalazine; also includes sulfasalazine, olsalazine.
yIncludes prednisolone, methylprednisolone, prednisone, beclometasone, betamethasone, cortisone acetate, hydrocortisone.
hsCRP, high-sensitivity C reactive protein; IQR, interquartile range.
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deﬁnitively rule out anti-drug antibodies, but these samples are
not available.
Efficacy results
Mayo scores
Overall response rates were higher with PF-00547,659 than
placebo at both week 4 (52% vs 32%, respectively; p¼0.102) and
week 12 (42% vs 21%, respectively; p¼0.156; multiple-dose
cohort only), but these differences did not reach statistical
signiﬁcance (ﬁgure 2A). Remission rates were similar in PF-
00547,659 and placebo groups at week 4 (13% and 11%, respec-
tively), but it may take longer to achieve full remission than
simply response, and by week 12 remission rates had risen to 22%
with PF-00547,659, while no patients on placebo remained in
remission (ﬁgure 2B). The difference in week 12 remission rates
between PF-00547,659 and placebo approached, but did not reach
statistical signiﬁcance (p¼0.056). When separate PF-00547,659
dose groups were considered, there was no clear pattern of
increasing response or remission rate with increasing PF-
00547,659 dose (ﬁgure 3). Endoscopic response and remission
rates were numerically, but not statistically higher, at both
timepoints, with PF-00547,659 than placebo (ﬁgure 2C,D).
Although complete mucosal healing rates were similar with PF-
00547,659 and placebo at week 4 (10% (6/60) vs 11% (2/19),
respectively), by week 12, 14% (5/36) of patients on active
treatment had complete mucosal healing compared with 0% (0/
14) of those on placebo. Examination of individual Mayo
component scores indicated that a reduction in rectal bleeding, as
well as endoscopic improvement/healing, contributed towards
the improvements in overall Mayo scores seen with PF-00547,659.
Biomarkers
The reduction in mean faecal calprotectin from baseline was
signiﬁcantly higher with PF-00547,659 than with placebo at
week 4 (63% vs 18%, respectively) and of borderline signiﬁcance
at week 12 (73% vs 34%, respectively) (ﬁgure 4A). At the indi-
vidual patient level, there was a trend for a high proportion of
patients in the PF-00547,659 group to have reductions in faecal
calprotectin from baseline to week 4 or week 12 (data not
shown). In the placebo group, individual patient responses were
highly variable and there was no clear trend for a reduction in
faecal calprotectin from baseline at either timepoint.
Clinically meaningful changes in plasma hsCRP could not be
detected as baseline levels were close to normal values (table 1).
Individual changes in plasma hsCRP from baseline with both PF-
00547,659 and placebo were also highly variable, with no
signiﬁcant differences in mean values between the two treat-
ments at week 4 (14% vs 28%, respectively) or 12 (57% vs
7%, respectively).
There was a trend for an increase from baseline in the number
of circulating CD4+ a4b7+ lymphocytes in patients receiving PF-
00547,659, but not in patients receiving placebo (table 3);
however, this was not statistically signiﬁcant due to a large
inter-subject variability. The effect was sustained at 4 weeks in
both the high-dose (1e10 mg/kg) and low-dose (0.03e0.3 mg/
kg) PF-00547,659 groups (ﬁgure 4B). The mean number of CD4+
a4b7
 cells in the high- and low-dose PF-00547,659 groups, and
the placebo group, remained close to baseline values throughout
the study (ﬁgure 4C). For both cell types, individual responses
were subject to considerable variation.
DISCUSSION
Blocking MAdCAM is a rational mechanism of action for
therapeutic intervention in IBD. MAdCAM represents an organ-
speciﬁc target, as expression is restricted mainly to gastrointes-
tinal tract mucosa.22 This organ speciﬁcity may translate to
a favourable safety proﬁle; in particular, the absence of
MAdCAM in the brain microvasculature32 suggests that drugs
acting on MAdCAM would not impact the body ’s ability to
respond to CNS infections such as PML.
Indeed, this ﬁrst-in-human trial of PF-00547,659 had a rela-
tively low incidence of non-gastrointestinal AEs. Gastrointes-
tinal AEs were common in both PF-00547,659 and placebo
groups, owing to the disease under study, and most AEs were
not considered to be treatment related. The majority of SAEs
occurred after follow-up and were related to underlying disease
rather than study drug. While nine patients (30%) discontinued
the single-dose phase and 20 (40%) discontinued the multiple-
dose phase of the study, only seven withdrew due to AEs.
Moreover, only one of these patient’s AEs were considered to be
related to the study drug. Overall, PF-00547,659 had an AE
proﬁle similar to placebo, and no safety concerns emerged in
laboratory tests or other safety monitoring.
Biological therapy is often associated with immunogenic
reactions, development of antidrug antibodies, which diminish
treatment response and can lead to infusion/injection site reac-
tions. PF-00547,659 is a fully human monoclonal antibody
developed using Abgenix XenoMouse technology (Amgen,
Thousand Oaks, California, USA), a platform that has yielded
antibodies with low intrinsic immunogenicity. In this study, no
antidrug antibodies were detected during treatment up to week
12 for all patients, and no injection site reactions were observed.
Longer-term studies, involving a much larger number of
patients, are required to conﬁrm a lack of immunogenicity with
Table 2 Adverse events occurring in $2 patients in placebo or
PF-00547,659 combined groups (single- and multiple-dose study phases
combined)
System organ class/preferred term
Percentage of patients with all-
cause (treatment-related) adverse
events
Placebo
(N[20)
PF-00547,659
(N[60)
Any adverse event 75 (20) 82 (37)
Severe adverse events 10 (0) 13 (5)
Headache 10 (5) 30 (13)
Abdominal pain* 25 (0) 20 (0)
Worsening of ulcerative colitis 15 (0) 13 (0)
Fatigue 10 (10) 13 (5)
Arthralgia 10 (0) 10 (3)
Influenza/influenza-like illness 0 (0) 10 (2)
Gastroenteritis/enteritis 5 (0) 8 (0)
Anaemiay 0 (0) 8 (2)
Nasopharyngitis 10 (0) 7 (2)
Respiratory tract infectionz 0 (0) 7 (2)
Nausea 10 (0) 5 (3)
Dizziness 5 (0) 5 (3)
Peripheral oedema 0 (0) 5 (2)
Back pain 15 (0) 3 (0)
Vomiting 5 (0) 3 (0)
Erythema 5 (5) 3 (0)
Insomnia (initial) 0 (0) 3 (3)
Eczema 0 (0) 3 (3)
Pruritis 0 (0) 3 (3)
Hot flush 0 (0) 3 (3)
Pain (not otherwise specified) 0 (0) 3 (0)
*Includes preferred terms abdominal pain, upper abdominal pain and lower abdominal pain.
yIncludes preferred terms anaemia and iron deficiency anaemia.
zIncludes preferred terms respiratory tract infection and upper respiratory tract infection.
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prolonged treatment (administered at clinically relevant doses)
and assess other aspects of long-term safety, including risk of
opportunistic infections, which only tend to become evident
with extended treatment. Biological agents for IBD are likely to
be subject to scrutiny in this regard following cases of PML with
long-term natalizumab therapy. Up to 80% of adults carry the
JC virus in a latent form, after being exposed during childhood.
The virus resides in the kidneys, bone marrow and the gastro-
intestinal tract and re-activation, most likely via the haemato-
genic route to the brain, causes PML. It is not clear if defective
homing of cytotoxic T cells to the brain or the appearance of
more virulent JC virus in the brain contribute to the risk of PML
as seen after natalizumab therapy.
This study investigated thepreliminary efﬁcacyof PF-00547,659
in patients whose ulcerative colitis is not controlled with
conventional therapy and found that, within small sample size
limitations, PF-00547,659 produced some potential beneﬁts
over placebo on clinical and endoscopic endpoints. However, no
statistical differences between PF-00547,659 and placebo were
reported for any efﬁcacy endpoints. Overall Mayo responder rates
were approximately 40e50% with PF-00547,659. No clear
doseeresponse relationship was observed with PF-00547,659,
Figure 2 Improvement in signs and
symptoms of ulcerative colitis with
PF-00547,659: overall clinical response
(*) and remission (y) rates and
endoscopic response (z) and remission
(x) rates based on Mayo scores at
week 4 and 12. (A) $3-point reduction
and 30% improvement in total Mayo
score (all components including
endoscopy $1 point), and a decrease in
rectal bleeding subscore, or absolute
rectal bleeding score of 0 or 1. (B) Total
Mayo score #2 points with no
individual subscore >1 point. (C) $1-
point improvement in Mayo endoscopic
subscore. (D) Mayo endoscopic
subscore of 0 or 1. p Values obtained
using one-sided Fisher’s exact test to
test the probability that active treatment
is associated with higher response/
remission rates than placebo. Week 4
data include all patients in single-dose
cohort and data for assessments
following the first dose for all patients in
multiple-dose cohorts. Week 12 data
include patients in the multiple-dose
cohort only.
Figure 3 Clinical response (A) and
remission (B) rates (based on total
Mayo score) at weeks 4 and 12 by
PF-00547,659 dose.
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although small groups (most doses administered to four patients)
and limited sensitivity of the clinical and endoscopic endpoints
confounded full exploration of doseeresponse relationships
within this initial study. The high discontinuation rate due to lack
of efﬁcacy (22/80)was not surprising for a patient populationwith
a fairly extensive, multidrug treatment history and advanced
disease that was not adequately controlled with conventional
medications.
Results of biomarker assays supported the clinical ﬁndings of
this study. Levels of faecal calprotectin, which reﬂects disease
activity and is a good predictor of disease course in ulcerative
colitis,35e37 declined in patients treated with PF-00547,659, and
were signiﬁcantly reduced with PF-00547,659 relative to placebo
at week 4. An increase in the number of CD4+ a4b7+ lympho-
cytes following PF-00547,659 administration, with no change in
CD4+ a4b7 cell numbers, was consistent with MAdCAM
blockade, and reﬂects the expected pharmacology that has been
reported in primate studies with PF-00547,659.33 It should be
noted, nonetheless, that individual lymphocyte responses were
subject to huge variation. Lack of change in a4b7 cell numbers
provided validation for the sensitivity of the assay to any
potential drug-related effects. As mean hsCRP levels were close
to normal levels at baseline and post-treatment changes were
subject to considerable variation, hsCRP was not considered
a useful biomarker for ulcerative colitis inﬂammation in this
study.
This ﬁrst-in-human study was conducted in patients with
ulcerative colitis, but the drug’s mechanism, blocking MAdCAM
to attenuate lymphocyte migration to the gut mucosa, would
also be expected to be effective in Crohn’s disease. The next
steps in development of the compound for either indication
should include fully powered dose-ranging studies, this time
applying an even gender distribution (which was skewed in the
Figure 4 Mean change from baseline
in biomarkers following dosing with
PF-00547,659 or placebo: faecal
calprotectin (A); CD4+ a4b7-positive
lymphocytes (B); CD4+ a4b7-negative
lymphocytes (C). (A) Baseline adjusted
geometric mean and associated 95% CI
are presented as a percentage change
from baseline. (B and C) Descriptive
statistics only. N numbers were variable
over the 28 days.
Table 3 Mean change in CD4+ a4b7-positive lymphocytes from
baseline in whole blood following dosing with PF-00547,659 or placebo
Placebo PF-00547,659
N
% change,
mean (SD) N
% change,
mean (SD)
Week 4* 8 12.7 (20.6) 32 44.6 (68.9)
Week 12y 5 0.4 (15.7) 10 46.5 (41.6)
*Combined data for single- and multiple-dose cohorts following the first dose.
yMultiple-dose cohorts only.
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present study due to the initial exclusion of women of child-
bearing potential). Dose selection for such studies can be guided
by pharmacokinetic proﬁles, which indicate that MAdCAM
becomes fully saturated at PF-00547,659 doses of 1 mg/kg or
higher,38 and levels of CD4+ a4b7+ lymphocytes, which showed
some differentiation of dose effect. Longer-term studies are
needed, to assess efﬁcacy in maintenance as well as induction of
remission, and to conﬁrm the apparently positive safety proﬁle
observed in this study.
In conclusion, the favourable short-term (typically 12e16-
week) safety proﬁle and preliminary efﬁcacy results observed
with the MAdCAM antibody PF-00547,659 in this ﬁrst-in-
human study pave the way for a further longer-term investiga-
tion of clinically relevant doses in larger numbers of patients, as
will be necessary to establish the potential role of PF-00547,659
in the treatment of IBD.
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